{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:20:57Z","timestamp":1790976057912,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cgh.2022.10.032","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T13:43:11Z","timestamp":1667569391000},"page":"1902-1912.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus"],"prefix":"10.1016","volume":"21","author":[{"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazneen","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"von Maltzahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Allinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-2255","authenticated-orcid":false,"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.10.032_bib1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.10.032_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.20276","article-title":"Quality of life in patients with primary biliary cirrhosis","volume":"40","author":"Poupon","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.10.032_bib3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/liv.14069","article-title":"Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus","volume":"39","author":"Hegade","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2022.10.032_bib4","series-title":"The pervasive impact of pruritis on quality of life in patients with primary biliary cholangitis (PBC): real world experience in TARGET-PBC","year":"2020"},{"key":"10.1016\/j.cgh.2022.10.032_bib5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/hep4.1173","article-title":"A\u00a0real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale","volume":"2","author":"Levy","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2022.10.032_bib6","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.10.032_bib7","first-page":"615","article-title":"Management of pruritus in patients with cholestatic liver disease","volume":"7","author":"Levy","year":"2011","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"10.1016\/j.cgh.2022.10.032_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818787400","article-title":"Cholestatic liver diseases: new targets, new therapies","volume":"11","author":"Santiago","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2022.10.032_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/flgastro-2015-100618","article-title":"A\u00a0systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis","volume":"7","author":"Hegade","year":"2016","journal-title":"Frontline Gastroenterology"},{"key":"10.1016\/j.cgh.2022.10.032_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11901-020-00517-x","article-title":"Newer approaches to the management of pruritus in cholestatic liver disease","volume":"19","author":"D\u00fcll","year":"2020","journal-title":"Current Hepatology Reports"},{"key":"10.1016\/j.cgh.2022.10.032_bib11","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.10.032_bib12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.10.032_bib13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/hepr.12830","article-title":"Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial","volume":"47","author":"Kumada","year":"2017","journal-title":"Hepatology Research"},{"key":"10.1016\/j.cgh.2022.10.032_bib14","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00535-018-1465-z","article-title":"Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? a post-marketing, single-arm, prospective study","volume":"53","author":"Yagi","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2022.10.032_bib15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.10.032_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12876-016-0481-9","article-title":"Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial","volume":"16","author":"Hegade","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2022.10.032_bib17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2022.10.032_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ejp.750","article-title":"Placebo and nocebo effects on itch: effects, mechanisms, and predictors","volume":"20","author":"Bartels","year":"2016","journal-title":"Eur J Pain"},{"key":"10.1016\/j.cgh.2022.10.032_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A\u00a0randomized, controlled, Phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2022.10.032_bib20","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2022.10.032_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522010217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522010217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:42:44Z","timestamp":1761543764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522010217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1542356522010217"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.10.032","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}